A technical deep-dive into why “99% purity” on a Certificate of Analysis tells you almost nothing — and what rigorous identity testing actually requires.

1. The GLP-1 Gold Rush and the Assumption That Breaks It

The global market for GLP-1 receptor agonists — semaglutide, tirzepatide, and the emerging triple agonist retatrutide — has grown faster than any regulatory framework can contain. Compounding pharmacies, research chemical vendors, and gray-market suppliers now move metric tons of peptide powder annually, nearly all of it accompanied by a Certificate of Analysis (CoA) declaring purity above 98% or 99%.

The assumption buyers make is simple: high purity = correct substance = safe and effective product.

That assumption is wrong on every level.

Purity testing answers one question: What fraction of the sample is the declared compound relative to impurities? It does not answer the question that matters first: Is the declared compound actually present? A sample can be 99% pure and contain zero semaglutide — if the 99% is a structurally similar analog, a degradation product, or an entirely different peptide that co-elutes under the chosen HPLC method.

This article lays out the analytical framework that serious buyers, compounders, and distributors must use to verify GLP-1 peptide identity before purity ever enters the conversation.

2. The Identity Problem: Why HPLC Alone Is Not Enough

2.1 The Co-Elution Trap

Reversed-phase HPLC (RP-HPLC) is the workhorse of peptide purity analysis. Under standard C18 gradient conditions, many GLP-1 peptides and their close structural relatives have overlapping retention times. Semaglutide and its des-amino degradation product, for example, can co-elute under suboptimal gradients. Tirzepatide and its C-terminal truncated variant may appear as a single peak if column resolution is insufficient.

A single HPLC peak at the expected retention time is not identity confirmation. It is, at best, a weak correlate — and in the gray market, a dangerously misleading one.

2.2 The Salt-Form Variable

GLP-1 peptides are almost universally supplied as acetate salts, sometimes as trifluoroacetate (TFA) salts, and occasionally as hydrochloride or other counterion forms. The peptide name on a CoA — “semaglutide acetate” — rarely specifies:

• The molar ratio of counterion to peptide
• The assay basis (peptide content vs. salt weight)
• The residual solvent contribution to total mass

A vial labeled “5 mg semaglutide” may contain 5 mg of acetate salt, of which only 3.8–4.2 mg is actual peptide. When that vial is reconstituted and dosed, the delivered active dose is materially lower than assumed. This is not fraud — it is a definitional ambiguity that the industry has failed to standardize, and that bad actors exploit.

2.3 The Analog Substitution Risk

The most dangerous failure mode is outright substitution. Structurally similar peptides — or even non-peptide small molecules with GLP-1 activity — can be sold as semaglutide or tirzepatide. Without mass spectrometry, substitution is essentially undetectable by HPLC alone.

3. The Analytical Hierarchy: A Four-Tier Verification Framework

Rigorous GLP-1 peptide verification proceeds in a specific order. Each tier builds on the one before it, and skipping a tier invalidates the conclusions of all subsequent tiers.

Tier 1: Molecular Weight Confirmation by LC-MS

Method: Liquid chromatography coupled to single-quadrupole or time-of-flight mass spectrometry (LC-MS).

What it tells you: The intact molecular mass of the principal peak, which must match the theoretical monoisotopic or average mass of the declared peptide within a defined tolerance (typically ±0.5 Da for peptides >3 kDa, ±5 ppm for high-resolution instruments).

Semaglutide reference mass: 4113.64 Da (average, free base)

Tirzepatide reference mass: 4813.53 Da (average, free base)

Retatrutide reference mass: 4902.06 Da (average, free base)

Critical caveat: LC-MS confirms mass, not structure. A peptide with the same molecular formula but different amino acid sequence (a structural isomer) will pass this test. For GLP-1 peptides, where the amino acid sequence is long and the probability of a mass-matching isomer being accidentally present is low, this is a strong first filter — but not a final answer.

Tier 2: Sequence Confirmation by Tandem Mass Spectrometry (MS/MS)

Method: Collision-induced dissociation (CID) or higher-energy collisional dissociation (HCD) of the parent ion, followed by analysis of the resulting b- and y-ion fragment series.

What it tells you: The actual amino acid sequence of the peptide, including:

• Correct amino acid identity at each position
• Presence or absence of post-translational modifications (the Aib substitution at position 2 in semaglutide, the fatty acid side chain)
• Correct disulfide bond connectivity (Cys⁶–Cys¹² in semaglutide and tirzepatide)
• C-terminal amidation status

Why it matters for GLP-1 peptides: Both semaglutide and tirzepatide contain non-standard amino acids and lipidated side chains. A generic “semaglutide” sample missing the C-18 fatty acid diacid side chain will have the correct core peptide mass (after Tier 1) but will be biologically inactive. Only MS/MS fragment mapping can confirm the side chain is present and attached at the correct lysine residue.

Acceptance criterion: A minimum of 70% sequence coverage by matched b/y ions, with all modified residues explicitly confirmed by diagnostic fragment ions.

Tier 3: Purity Quantification by Validated HPLC Method

Method: RP-HPLC with UV detection at 214 nm (peptide bond absorbance) or 280 nm (aromatic residue absorbance), using a validated gradient on a suitable C18 or C4 column.

What it tells you: The percentage of the declared peptide relative to all detectable impurities, including:

• Related peptide impurities (truncated, oxidized, deamidated forms)
• Residual counterions (acetate, TFA) — these are typically invisible at 214/280 nm and require separate ion chromatography or NMR
• Residual solvents (by headspace GC)

Method validation requirements: A purity method is only meaningful if it has been shown to:

• Resolve the target peptide from known related substances
• Have a linear response across the relevant concentration range
• Have acceptable precision (RSD < 2% for replicate injections)
• Use an appropriate detection wavelength that does not favor or disfavor specific impurities

The 214 nm vs. 280 nm problem: GLP-1 peptides contain tryptophan, tyrosine, and phenylalanine residues. At 280 nm, the extinction coefficient is dominated by these aromatic residues. Impurities lacking aromatic residues (e.g., N-terminal truncated fragments) will be under-represented or invisible. At 214 nm, all peptide bonds absorb, providing a more representative purity profile — but the method is more sensitive to buffer and solvent interference. A rigorous report provides both wavelengths and reconciles the difference.

Tier 4: Peptide Content and Counterion Analysis

Method: Amino acid analysis (AAA) or quantitative NMR (qNMR) for peptide content; ion chromatography (IC) for acetate/TFA counterion quantitation; Karl Fischer titration for water content.

What it tells you: The actual mass of active peptide per unit weight of the supplied material — the number that determines dosing.

The calculation:

Peptide Content (%) = Purity (%) × (1 − Water% − Counterion% − Residual Solvent%)

A sample with 99% HPLC purity, 5% water, 8% acetate, and 0.5% residual TFA has a true peptide content of approximately 85.7% — not 99%. This is the single most under-reported figure in the peptide supply chain, and the one with the greatest direct impact on end-user dosing.

4. The CoA Authenticity Problem

A Certificate of Analysis is only as credible as the laboratory that issued it. In the gray-market peptide trade, CoA fraud takes three primary forms:

4.1 Fabricated CoAs

Entirely counterfeit documents, often with invented laboratory names, fake logos, and plausible-looking data. These are trivially easy to produce and common among low-tier vendors.

Red flags:

• No verifiable laboratory address or accreditation
• Generic email addresses (Gmail, Yahoo) as contact points
• Results that are suspiciously consistent across batches (e.g., every batch is exactly 99.2% pure)
• No raw chromatograms or spectral data available upon request

4.2 Cherry-Picked CoAs

The vendor tests multiple batches, selects the best result, and prints that CoA for every batch sold. The material shipped may be from an untested or lower-quality batch.

Detection: Request batch-specific raw data (chromatograms, mass spectra) and verify that the batch number on the CoA matches the manufacturing label on the vial or drum.

4.3 Method-Obscured CoAs

The CoA reports a high purity number but uses an analytical method known to under-represent impurities — for example, a short HPLC gradient that cannot resolve closely related impurities, or a detection wavelength that makes certain impurities invisible.

Detection: Require full method disclosure (column type, gradient, detection wavelength, injection volume, sample concentration) and cross-reference against published pharmacopeial methods where available.

5. Sampling: The Forgotten Variable

Even a perfect analytical method produces a meaningless result if the sample tested is not representative of the material shipped.

5.1 Homogeneity Concerns

Peptide powders are not always homogeneous. Lyophilized peptides can segregate by particle size during transport. Acetate content can vary within a single batch if lyophilization was uneven. A sample taken from the top of a drum may not represent the bottom.

Best practice: For bulk quantities (>10 g), composite sample from at least three locations (top, middle, bottom) and homogenize before analysis. For vialed product, test multiple vials from the same lot.

5.2 Degradation in Transit

GLP-1 peptides are sensitive to temperature, moisture, and oxidation. A sample that was pure when manufactured may degrade during unrefrigerated shipping. Deamidation of asparagine residues, oxidation of methionine and tryptophan, and aggregation are all documented degradation pathways for semaglutide and tirzepatide.

Best practice: Ship samples under refrigeration (2–8°C) with desiccant, and document the cold chain. Test upon arrival and compare against the supplier’s CoA — a significant drop in purity indicates either a shipping failure or a CoA that does not represent the shipped material.

6. Building a Defensible Testing Program

For organizations that source GLP-1 peptides for compounding, research, or distribution, a defensible quality program requires the following minimum standards:

6.1 The Independent Testing Principle

No supplier’s in-house CoA should be accepted as the sole basis for quality determination. Independent third-party testing serves two functions:

1. Verification: It confirms that the supplier’s results are accurate and reproducible.
2. Deterrence: Suppliers who know their customers independently test are less likely to ship substandard material.

The cost of independent testing — typically $150–$500 per batch for identity + purity — is trivial compared to the liability of distributing an incorrectly identified or under-potent peptide product.

7. Conclusion: Identity Is the Foundation, Not a Formality

The GLP-1 peptide market will continue to grow, and regulatory oversight will continue to lag. In this environment, the responsibility for verifying what is actually in the vial falls to the buyer.

The framework presented here — mass confirmation → sequence confirmation → purity quantification → content determination — is not optional. It is the minimum analytical rigor required to distinguish a genuine GLP-1 receptor agonist from a substituted analog, a degraded sample, or a well-formulated fraud.

Purity without identity is a meaningless number. Identity without content is an uncontrolled dose. Only the full framework, applied consistently and verified independently, provides the assurance that serious stakeholders in this market require.

The laboratories that understand this — and the buyers who demand it — will be the ones that survive the inevitable regulatory consolidation of this industry. The rest will be exposed when the first major adverse event traces back to a vial that was “99% pure” and entirely wrong.

This article is for informational and educational purposes only and does not constitute medical, legal, or regulatory advice. Peptide compounds, including GLP-1 receptor agonists, are subject to significant regulatory restrictions in many jurisdictions. Readers are responsible for ensuring compliance with all applicable laws and regulations in their respective jurisdictions.